| ID Source | ID |
|---|---|
| PubMed CID | 643801 |
| CHEBI ID | 84156 |
| SCHEMBL ID | 440468 |
| MeSH ID | M0186227 |
| Synonym |
|---|
| ai3-36450 |
| einecs 214-303-2 |
| 35695qdb9f , |
| unii-35695qdb9f |
| methyl palmitoleate , |
| 9-hexadecenoic acid, methyl ester, (z)- |
| inchi=1/c17h32o2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17(18)19-2/h8-9h,3-7,10-16h2,1-2h3/b9-8 |
| 9-hexadecenoic acid, methyl ester, (9z)- |
| methyl (9z)-hexadec-9-enoate |
| methyl palmitoleate, >=99% (capillary gc), liquid |
| 0A07894A-8C05-4940-9DC5-451562B136DF |
| hexadecenoic acid methyl ester, 9-(z)- |
| palmitoleic acid methyl ester |
| 1120-25-8 |
| methyl (z)-hexadec-9-enoate |
| methyl 9z-hexadecenoate |
| we(1:0/16:1(9z)) |
| LMFA07010501 |
| cis-9-hexadecenoic acid methyl ester |
| methyl cis-9-hexadecenoate |
| P1958 |
| AKOS016013143 |
| methyl palmitoleate [usp-rs] |
| SCHEMBL440468 |
| z9-hexadecenoic acid methyl ester |
| methyl palmitoleinate |
| cis-9-hexadecenoic acid, methyl ester |
| palmitoleic acid, methyl ester |
| CHEBI:84156 |
| methyl cis-hexadec-9-enoate |
| methyl z-9-hexadecenoate |
| methyl palmitioleate |
| methyl (9z)-9-hexadecenoate # |
| AC-33776 |
| (z)-methyl hexadec-9-enoate |
| mfcd00042911 |
| formyl 9z-hexadecenoate |
| J-002692 |
| methyl palmitoleate, analytical standard |
| methyl palmitoleate, united states pharmacopeia (usp) reference standard |
| AS-59087 |
| palmitoleic acid-methyl ester |
| (z)methyl hexadec-9-enoate |
| Q27157517 |
| c17h32o2 (cis-hexadec-9-enoic acid methyl ester) |
| methyl cis-palmitoleate |
| CS-W012404 |
| DTXSID00897351 |
| HY-W011688 |
| Class | Description |
|---|---|
| fatty acid methyl ester | A fatty acid ester that is the carboxylic ester obtained by the formal condensation of a fatty acid with methanol. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (30.13) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||